Compare Comcast Corporation (CMCSA) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs Medtronic PLC — how do they compare? Comcast Corporation trades at $25.46 (market cap $91.02B), while Medtronic PLC trades at $90.77 (market cap $116.07B). The key difference: Medtronic PLC is the larger of the two by market cap, and Comcast Corporation pays the higher dividend (5.15%). Which is the better fit depends on your goals.
| CMCSA | MDT | |
|---|---|---|
Market Cap | $91.02B | $116.07B |
Sector | Media | Health |
52-Week High | $32.50 | $105.35 |
52-Week Low | $21.92 | $73.75 |
Enterprise Value | $173.74B | $134.82B |
Dividend Yield | 5.15% | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comcast (CMCSA) trades at $25.35, up 0.6% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.04 versus $0.97 expected, driven by wireless growth and Peacock profitability. Recent news highlights expansion of high-speed internet services and strategic initiatives like the NBCUniversal spinoff. Fundamentals show robust cash flow generation, with 2025 operating cash flow at $33.64 billion, and attractive valuation metrics including a P/E of 8.22 and EV/EBITDA of 5.09.
The outlook for CMCSA is positive, supported by analyst consensus with a $27.78 price target and 55.74% buy ratings. Investment opportunities include the potential upside from the NBCUniversal separation and sustained dividend payments. Key risks involve competitive pressures in broadband, theme park volatility, and integration challenges from corporate restructuring. The stock offers value with solid fundamentals but faces execution risks in a dynamic media landscape.
Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.
The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
